NIH-CSR <script type="text/javascript"> var wmNotice = "UNT Web Archive - External links, forms, and search boxes may not function within this collection. Url: http://cms.csr.nih.gov/PeerReviewMeetings/CSRIRGDescription/HEMEIRG/HEMESEPS.htm time: 14:58:51 Sep 20, 2008"; var wmHideNotice = "hide"; var contextRoot = "https://webarchive.library.unt.edu/eot2008/"; </script> <script type="text/javascript" src="https://webarchive.library.unt.edu/eot2008/js/disclaim.js"></script> <span id="Postingname3_PostingDisplayName">Hematology Small Business Activities [SBIR/STTR] Special Emphasis Panel [HEME Small Business SEP]</span> (HEMEIRG)

Specific areas covered by the HEME Small Business SEP:

The Hematology Small Business Activities Special Emphasis Panel [HEME Small Business SEP] will review SBIR and STTR applications ranging from basic research through clinical studies focused on red blood cells and their diseases including sickle cell anemia, storage of whole blood and its components, transfusion medicine, development of blood substitutes, stem cell culture, and stem cell therapy, hematopoiesis, studies of normal and pathologic hemostasis and thrombosis including hemophilia and gene therapy, anticoagulant therapy and development of hematological diagnostic devices and assays.

The HEME Small Business SEP has the following shared interests outside the HEME IRG:

With the Biology of Development and Aging [BDA] IRG: Applications focused on hematopoietic stem cells or gene transfer therapies are relevant to the HEME Small Business SEP. Similarly, applications that focus on stem cells in early developmental would be assigned to the BDA IRG. Applications that use human embryonic stem cells might also be clustered in the BDA IRG, even if studying hematopoietic system specific issues.
With the Bioengineering Sciences and Technologies [BST] IRG: (1) Where the response of blood elements to medical devices and systems are primary foci, assignment to the HEME Small Business SEP might be appropriate. Where the issues are development of new materials or biocompatibility, assignment to the BST IRG may be considered. (2) Applications focused on specific hematological stem cell or gene transfer therapies are relevant to the HEME Small Business SEP. Applications focused on developing stem cell and gene transfer technologies to introduce genes and drugs in a general context are relevant to the BST IRG.
With the Risk, Prevention, and Health Behavior [RPHB] IRG and the Health of the Population [HOP] IRG: Studies on behavior modification, including health education or training, directed toward the prevention and treatment of hematological diseases, including psychological aspects, could be assigned to the RPHB IRG or to the HOP IRG, depending upon the level of analysis and the nature of the intervention. Applications focused on hematological diseases, disorders, or functional consequences of behaviors could be assigned to the HEME Small Business SEP. Health education or training directed to the health care provider, not the patient, should also be assigned to the HEME Small Business SEP.
With the Cardiovascular Sciences [CVS] IRG: Shared interest may exist concerning the use of common stem cell precursors. Assignment of applications that involve the transdifferentiation of cells between the blood and endothelial cell types would be resolved in the direction of the final phenotype, i.e., stem cell plasticity. For example, if the final phenotype of the differentiated tissue is a blood cell the application may be assigned to the HEME Small Business SEP. If the final phenotype of the differentiated tissue is a vascular smooth muscle cells then assignment to the CVS IRG may be appropriate.